Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Liabilities: 2019-2021

Historic Other Non-Current Liabilities for Keros Therapeutics (KROS) over the last 2 years, with Sep 2021 value amounting to $16,000.

  • Keros Therapeutics' Other Non-Current Liabilities fell 79.22% to $16,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $16,000, marking a year-over-year decrease of 79.22%. This contributed to the annual value of $62,000 for FY2020, which is 47.90% down from last year.
  • Latest data reveals that Keros Therapeutics reported Other Non-Current Liabilities of $16,000 as of Q3 2021, which was down 50.00% from $32,000 recorded in Q2 2021.
  • In the past 5 years, Keros Therapeutics' Other Non-Current Liabilities registered a high of $119,000 during Q4 2019, and its lowest value of $16,000 during Q3 2021.
  • Its 3-year average for Other Non-Current Liabilities is $68,500, with a median of $69,500 in 2020.
  • Data for Keros Therapeutics' Other Non-Current Liabilities shows a maximum YoY tumbled of 79.22% (in 2021) over the last 5 years.
  • Keros Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $119,000 in 2019, then crashed by 47.90% to $62,000 in 2020, then tumbled by 79.22% to $16,000 in 2021.
  • Its Other Non-Current Liabilities was $16,000 in Q3 2021, compared to $32,000 in Q2 2021 and $47,000 in Q1 2021.